A significant reduction in hepatitis B virus infection among the children of Shandong Province, China: the effect of 15 years of universal infant hepatitis B vaccination

Int J Infect Dis. 2010 Jun;14(6):e483-8. doi: 10.1016/j.ijid.2009.08.005. Epub 2009 Nov 25.

Abstract

Objective: To evaluate the effect of the universal infant hepatitis B vaccination program on hepatitis B infection in China.

Methods: In 2006, a survey was conducted in Shandong Province, China, among children aged 1-14 years, 15 years after the introduction of universal infant hepatitis B vaccination. The subjects were selected by stratified, multi-stage sampling. Vaccination history was obtained by immunization certificate (when available) or parent recall. Hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) and core antigen (anti-HBc) were detected by ELISA. Hepatitis B infection was defined as the presence of HBsAg and/or anti-HBc. The prevalence rates of HBsAg, anti-HBs and hepatitis B infection obtained in this survey were compared with the results of a survey conducted in 1992 (prior to universal vaccination).

Results: A total of 3738 children aged 1-14 years were included in the final analysis. A vaccination coverage rate of 93% was achieved in 2006. The prevalence rates of HBsAg and hepatitis B infection decreased from 8% and 46% in the 1992 survey to 1% and 4%, respectively, in the 2006 survey.

Conclusions: Universal hepatitis B vaccination in infants can result in a 90.47% reduction in hepatitis B infection in children aged 1-14 years.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • China / epidemiology
  • Female
  • Hepatitis B / blood
  • Hepatitis B / epidemiology*
  • Hepatitis B / prevention & control*
  • Hepatitis B Antibodies / blood
  • Hepatitis B Antibodies / immunology
  • Hepatitis B Core Antigens / immunology
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B Vaccines / administration & dosage*
  • Humans
  • Immunization Programs*
  • Infant
  • Male
  • Mass Vaccination*
  • Program Evaluation
  • Seroepidemiologic Studies

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines